Abstract 440P
Background
Targeted therapy is emerging as the frontline of cancer treatment due to improved clinical outcomes and enhanced quality of life among cancer patients. However, treatments related to adverse events (AEs) of targeted therapy are associated with the outcome of cancer treatments. This study investigated the frequency and severity of adverse events in cancer patients who receive targeted therapy.
Methods
The study was conducted at a university hospital in northern Thailand, from January to June 2023. We performed a retrospective study concerning patients treated with targeted therapy including multikinase inhibitors, epidermal-growth factors (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, cyclin-dependent kinases 4 and 6 (CDK4/6), immune checkpoint inhibitors (ICIs), mammalian target of rapamycin (mTOR) inhibitors, and phosphoinositide 3-kinases (PI3Ks) inhibitors. All adverse events were reported by pharmacists and confirmed by medical oncologists in electronic medical record (EMR) based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Descriptive statistics were applied for reporting frequency of AEs.
Results
There are 136 cancer patients with targeted therapy. The majority of patients were female (58.1%) with mean age 64.0 ± 11.9 years old. Non-small cell lung cancer is the most common cancer (47.1%) followed by hepatocellular carcinoma (14.7%) and breast cancer (11%). The frequency of targeted therapy treatment was erlotinib (18.4%), ceritinib (18.4%), regorafenib (10.3%) and ribociclib (8.1%). Eighty-two patients (60.3%) reported AEs. The most AEs were grade 1-2 (64%). Skin rash was the most common AE (22.8%), subsequently with dry skin (16.9%) and diarrhea (14.7%). Six patients (4.4%) had grade 3 AEs including skin rash (0.7%), Hand foot skin reaction (0.7%), transaminitis (1.5%), and neutropenia (1.5%).
Conclusions
This study demonstrated the frequency of AEs among cancer patients with targeted therapy, the most common AEs included dermatological problems. Rarely severe AEs were reported. Health care providers will need to educate and monitor cancer patients to prevent and monuments AEs during targeted therapy treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract